FAQ: Emily Johns' Promotion to Chief Administrative Officer at NeuroOne
Summary
NeuroOne Medical Technologies Corporation has promoted Emily Johns to Chief Administrative Officer and General Counsel, expanding her responsibilities to include human resources, compliance, security, and risk management. This promotion recognizes her significant contributions to the company and supports NeuroOne's growth strategy as it develops neurological disorder treatments.
What is the main announcement in this press release?
NeuroOne Medical Technologies Corporation has promoted Emily Johns to the expanded role of Chief Administrative Officer and General Counsel, where she will continue leading legal strategy while also overseeing human resources, compliance, security, and risk management.
Who is Emily Johns and what is her background?
Emily Johns is an experienced public company lawyer who joined NeuroOne earlier this year as General Counsel. She previously served as a partner at Honigman LLP, represented NeuroOne on transactional work since 2017, and began her career at Sullivan & Cromwell LLP, with degrees from UCLA School of Law and the University of Michigan.
Why was Emily Johns promoted according to NeuroOne’s CEO?
CEO Dave Rosa stated that Johns has made impactful contributions to the organization and the future growth of the business in the short time she has been with NeuroOne, and they look forward to her future contributions as the company continues to scale.
What additional responsibilities does Emily Johns now have in her expanded role?
In addition to continuing as General Counsel, Johns will now oversee all human resources, compliance, security, and risk areas of the organization as Chief Administrative Officer.
When did this promotion take effect?
The promotion was announced on October 16, 2025, though the exact effective date is not specified in the press release.
What does NeuroOne Medical Technologies Corporation do?
NeuroOne is a medical technology company focused on developing and commercializing minimally invasive and hi-definition solutions for EEG recording, stimulation, and ablation for patients suffering from neurological disorders such as epilepsy, Parkinson’s disease, dystonia, and essential tremors.
What did Emily Johns say about her new role?
Johns stated she is honored to step into this role and continue building on the strong foundation the team has created, and she looks forward to strengthening operations and infrastructure to help bring NeuroOne’s life-changing technologies to more people.
Where can I find more information about NeuroOne?
For more information about NeuroOne Medical Technologies Corporation, you can visit their website at www.nmtc1.com.
What is the significance of this promotion for NeuroOne’s future?
This promotion supports NeuroOne’s business scaling efforts by strengthening operational infrastructure and legal oversight, which will help the company bring its neurological treatment technologies to more patients while managing growth-related risks.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire
Article Control ID: 255050